

Date	Change Made	Made By
10/27/2023	Added a change log tab to note major updates or corrections to the document.	Staff
10/27/2023	Added the "Detailed data Aggregated by Name" tab, which aggregates values from the APAC data tab by the drug's proprietary name.	Staff
10/27/2023	Updated the Novolog mix as "no" under the IRA CMS column. Reviewed the fact sheet of the CMS negotiated drugs and it does not appear the Novolog mix may be included in the forms of Novolog listed on the fact sheet.	Staff
10/27/2023	Added the "Detailed data Aggregated by Drug Base " tab, which aggregates values from the APAC data tab by the drug base.	Staff

Drug type detail				2022 Volume data	2022 Cost data	Comparison of 2022 and 2021	Generic and Biosimilar Information	FDA approval data	WAC data	
Year	Insulin Type FDA	Proprietary name	Non-proprietary name	Claimants	2022 per patient spend	Percent change per patient spend 2021-2022	Drug has a therapeutic equivalent or biosimilar	Exclusivity expiration date within 18 months	Avg YoY price change (over past 5 years)	Drug part of IRA CMS negotiation list
2022	Rapid-Acting	Insulin Aspart	Insulin Aspart	847	\$2,266.13	10%	None Listed	No	0.00%	No
2022	Rapid-Acting	Insulin Aspart FlexPen	Insulin Aspart	1,401	\$1,354.42	-1%	None Listed	No	0.00%	No
2022	Rapid-Acting	Insulin Aspart PenFill	Insulin Aspart	195	\$1,977.42	3%	None Listed	No	0.00%	No
2022	Rapid-Acting	NovoLOG	Insulin Aspart	863	\$6,210.43	14%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	NovoLOG FlexPen	Insulin Aspart	960	\$4,112.32	4%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	NovoLOG FlexPen ReliOn	Insulin Aspart	108	\$378.95	116%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	NovoLOG PenFill	Insulin Aspart	125	\$4,936.06	34%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	NovoLOG ReliOn	Insulin Aspart	46	\$1,070.00	100%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	Fiasp	Insulin Aspart (with Niacinamide)	108	\$4,933.83	5%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	Fiasp FlexTouch	Insulin Aspart (with Niacinamide)	158	\$4,358.16	35%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	Fiasp PenFill	Insulin Aspart (with Niacinamide)	21	\$4,782.95	81%	None Listed	No	0.00%	Yes
2022	Rapid-Acting	Apidra	Insulin Glulisine	9	\$4,505.99	1%	None Listed	No	1.04%	No
2022	Rapid-Acting	Apidra SoloStar	Insulin Glulisine	14	\$6,743.84	14%	None Listed	No	1.04%	No
2022	Rapid-Acting	Admelog	Insulin Lispro	443	\$1,251.05	-24%	None Listed	No	-11.30%	No
2022	Rapid-Acting	Admelog SoloStar	Insulin Lispro	1,102	\$1,097.42	-22%	None Listed	No	-13.80%	No
2022	Rapid-Acting	HumaLOG	Insulin Lispro	2,995	\$3,760.24	3%	None Listed	No	0.00%	No
2022	Rapid-Acting	HumaLOG Junior KwikPen	Insulin Lispro	301	\$2,143.50	12%	None Listed	No	0.00%	No
2022	Rapid-Acting	HumaLOG KwikPen	Insulin Lispro	2,703	\$3,159.55	0%	None Listed	No	0.00%	No
2022	Rapid-Acting	Insulin Lispro	Insulin Lispro	796	\$1,100.61	-29%	None Listed	No	-32.00%	No
2022	Rapid-Acting	Insulin Lispro (1 Unit Dial)	Insulin Lispro	969	\$711.32	-38%	None Listed	No	-11.67%	No
2022	Rapid-Acting	Insulin Lispro Junior KwikPen	Insulin Lispro	114	\$693.06	-22%	None Listed	No	-13.33%	No
2022	Rapid-Acting	Lyumjev	Insulin Lispro-aabc	76	\$5,477.09	39%	None Listed	No	0.00%	No
2022	Rapid-Acting	Lyumjev KwikPen	Insulin Lispro-aabc	89	\$3,517.45	43%	None Listed	No	0.00%	No
2022	Rapid-Acting	Afrezza	Insulin Regular (Human)	9	\$11,480.48	15%	None Listed	No	6.80%	No
2022	Short-Acting	HumuLIN R	Insulin Regular (Human)	1,686	\$615.39	-2%	None Listed	No	0.00%	No
2022	Short-Acting	HumuLIN R U-500 (CONCENTRATED)	Insulin Regular (Human)	115	\$10,694.73	-15%	None Listed	No	0.00%	No
2022	Short-Acting	HumuLIN R U-500 KwikPen	Insulin Regular (Human)	157	\$12,064.03	-3%	None Listed	No	0.00%	No
2022	Short-Acting	NovoLIN R	Insulin Regular (Human)	100	\$1,617.76	8%	None Listed	No	0.00%	No
2022	Short-Acting	NovoLIN R FlexPen	Insulin Regular (Human)	34	\$1,007.53	28%	None Listed	No	0.00%	No
2022	Short-Acting	NovoLIN R FlexPen ReliOn	Insulin Regular (Human)	3	\$80.04	-57%	None Listed	No	0.00%	No
2022	Short-Acting	NovoLIN R ReliOn	Insulin Regular (Human)	25	\$195.95	-14%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	Insulin Asp Prot & Asp FlexPen	Insulin Aspart Protamine & Aspart (Human)	102	\$1,727.91	-9%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	Insulin Aspart Prot & Aspart	Insulin Aspart Protamine & Aspart (Human)	17	\$1,554.49	50%	None Listed	No	0.00%	No

Year	Insulin Type FDA	Proprietary name	Non-proprietary name	Claimants	2022 per patient spend	Percent change per patient spend 2021-2022	Drug has a therapeutic equivalent or biosimilar	Exclusivity expiration date within 18 months	Avg YoY price change (over past 5 years)	Drug part of IRA CMS negotiation list
2022	Intermediate and Rapid-Acting	NovoLOG 70/30 FlexPen ReliOn	Insulin Aspart Protamine & Aspart (Human)	12	\$728.55	294%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	NovoLOG Mix 70/30	Insulin Aspart Protamine & Aspart (Human)	17	\$3,429.06	-28%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	NovoLOG Mix 70/30 FlexPen	Insulin Aspart Protamine & Aspart (Human)	44	\$5,594.52	8%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	NovoLOG Mix 70/30 ReliOn	Insulin Aspart Protamine & Aspart (Human)	5	\$466.43	No 2021 Data	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	HumaLOG Mix 50/50	Insulin Lispro Protamine & Lispro	2	\$1,006.48	136%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	HumaLOG Mix 50/50 KwikPen	Insulin Lispro Protamine & Lispro	7	\$3,654.42	-8%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	HumaLOG Mix 75/25	Insulin Lispro Protamine & Lispro	9	\$7,439.25	-2%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	HumaLOG Mix 75/25 KwikPen	Insulin Lispro Protamine & Lispro	49	\$6,512.12	8%	None Listed	No	0.00%	No
2022	Intermediate and Rapid-Acting	Insulin Lispro Prot & Lispro	Insulin Lispro Protamine & Lispro	16	\$893.67	-33%	None Listed	No	-13.33%	No
2022	Intermediate and Short-Acting	HumuLIN 70/30	Insulin NPH Isophane & Reg (Human)	315	\$1,136.49	8%	None Listed	No	0.00%	No
2022	Intermediate and Short-Acting	HumuLIN 70/30 KwikPen	Insulin NPH Isophane & Reg (Human)	89	\$3,448.16	-1%	None Listed	No	0.00%	No
2022	Intermediate and Short-Acting	NovoLIN 70/30	Insulin NPH Isophane & Reg (Human)	72	\$1,703.14	-4%	None Listed	No	0.00%	No
2022	Intermediate and Short-Acting	NovoLIN 70/30 FlexPen	Insulin NPH Isophane & Reg (Human)	79	\$1,930.59	13%	None Listed	No	0.00%	No
2022	Intermediate and Short-Acting	NovoLIN 70/30 FlexPen ReliOn	Insulin NPH Isophane & Reg (Human)	13	\$127.32	8%	None Listed	No	0.00%	No
2022	Intermediate and Short-Acting	NovoLIN 70/30 ReliOn	Insulin NPH Isophane & Reg (Human)	28	\$417.63	11%	None Listed	No	0.00%	No
2022	Intermediate-Acting	HumuLIN N	Insulin NPH (Human) (Isophane)	3,767	\$703.04	0%	None Listed	No	0.00%	No
2022	Intermediate-Acting	HumuLIN N KwikPen	Insulin NPH (Human) (Isophane)	498	\$1,349.64	-8%	None Listed	No	0.00%	No
2022	Intermediate-Acting	NovoLIN N	Insulin NPH (Human) (Isophane)	280	\$1,052.50	1%	None Listed	No	0.00%	No
2022	Intermediate-Acting	NovoLIN N FlexPen	Insulin NPH (Human) (Isophane)	149	\$737.62	-5%	None Listed	No	0.00%	No
2022	Intermediate-Acting	NovoLIN N FlexPen ReliOn	Insulin NPH (Human) (Isophane)	29	\$140.03	24%	None Listed	No	0.00%	No
2022	Intermediate-Acting	NovoLIN N ReliOn	Insulin NPH (Human) (Isophane)	83	\$186.82	-17%	None Listed	No	0.00%	No
2022	Long-Acting	Tresiba	Insulin Degludec	76	\$3,016.12	9%	None Listed	No	0.98%	No
2022	Long-Acting	Tresiba FlexTouch	Insulin Degludec	2,279	\$4,000.04	1%	None Listed	No	0.98%	No

Year	Insulin Type FDA	Proprietary name	Non-proprietary name	Claimants	2022 per patient spend	Percent change per patient spend 2021-2022	Drug has a therapeutic equivalent or biosimilar	Exclusivity expiration date within 18 months	Avg YoY price change (over past 5 years)	Drug part of IRA CMS negotiation list
2022	Long-Acting	Levemir	Insulin Detemir	116	\$2,804.16	-14%	None Listed	No	0.98%	No
2022	Long-Acting	Levemir FlexTouch	Insulin Detemir	692	\$2,850.49	-12%	None Listed	No	0.98%	No
2022	Long-Acting	Basaglar KwikPen	Insulin Glargine	4,477	\$1,761.69	-5%	None Listed	No	0.00%	No
2022	Long-Acting	Lantus	Insulin Glargine	1,782	\$1,952.19	-18%	Yes	No	1.34%	No
2022	Long-Acting	Lantus SoloStar	Insulin Glargine	4,336	\$2,576.32	-2%	Yes	No	1.34%	No
2022	Long-Acting	Semglee	Insulin Glargine	51	\$167.35	-39%	Yes	No	0.00%	No
2022	Long-Acting	Toujeo Max SoloStar	Insulin Glargine	483	\$5,487.97	-2%	None Listed	No	1.88%	No
2022	Long-Acting	Toujeo SoloStar	Insulin Glargine	776	\$3,667.33	-9%	None Listed	No	1.88%	No
2022	Long-Acting	Xultophy	Insulin Degludec-Liraglutide	14	\$8,608.74	16%	None Listed	No	4.56%	No
2022	Long-Acting	Soliqua	Insulin Glargine-Lixisenatide	39	\$4,089.51	14%	None Listed	No	4.78%	No

Drug type detail

2022 Volume data 2022 Cost data Comparison of 2022 and 2021 Generic and Biosimilar Information FDA approval data WAC data

Year	Insulin Type FDA	Drug base name	Proprietary names	Claimants	2022 per patient spend	Percent change per patient spend 2021-2022	Drug has a therapeutic equivalent or biosimilar	Exclusivity expiration date within 18 months	Avg YoY price change (over past 5 years)	Drugs with drug base part of IRA CMS negotiation list
2022	Rapid-Acting	Insulin Aspart	Fiasp/ Insulin Aspart/ NovoLOG	4,832	\$3,215.86	8%	No	No	0%	Yes
2022	Rapid-Acting	Insulin Glulisine	Apidra	23	\$5,868.16	8%	No	No	1%	No
2022	Rapid-Acting	Insulin Lispro	Admelog/ HumaLOG/ Insulin Lispro/ Lyumjev	9,588	\$2,564.10	-3%	No	No	-8%	No
2022	Rapid-Acting	Insulin Regular (Human)	Afrezza	9	\$11,480.48	15%	No	No	7%	No
2022	Short-Acting	Insulin Regular (Human)	HumuLIN R/ NovoLIN R	2,120	\$2,057.86	-4%	No	No	0%	No
2022	Intermediate and Rapid-Acting	Insulin Aspart Protamine & Aspart (Human)	Insulin Aspart Prot & Aspart/ NovoLOG Mix 70/30	197	\$2,630.46	-27%	No	No	0%	No
2022	Intermediate and Rapid-Acting	Insulin Lispro Protamine & Lispro	HumaLOG Mix 50/50/ HumaLOG Mix 75/25/ Insulin Lispro Prot & Lispro	83	\$5,155.90	5%	No	No	-3%	No
2022	Intermediate and Short-Acting	Insulin NPH Isophane & Reg (Human)	HumuLIN 70/30/ NovoLIN 70/30	596	\$1,599.62	7%	No	No	0%	No
2022	Intermediate-Acting	Insulin NPH (Human) (Isophane)	HumuLIN N/ NovoLIN N	4,806	\$779.16	0%	No	No	0%	No
2022	Long-Acting	Insulin Degludec	Tresiba	2,355	\$3,968.28	1%	No	No	1%	No
2022	Long-Acting	Insulin Detemir	Levemir	808	\$2,843.84	-12%	No	No	1%	No
2022	Long-Acting	Insulin Glargine	Basaglar KwikPen/ Lantus/ Semglee/ Toujeo SoloStar	11,905	\$2,355.47	-5%	Yes	No	1%	No
2022	Long-Acting	Insulin-Incretin Mimetic Combination - Two Ingredient	Soliqua/ Xultophy	53	\$5,283.27	5%	No	No	5%	No